Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non‐small cell lung cancer

Enrolling patients in immunotherapy clinical trials is becoming increasingly competitive. Virtual clinical trials can help investigators answer key questions despite this. For example, pembrolizumab is the recommended first‐line treatment for non‐small cell lung cancer (NSCLC) with no driver alterat...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Timothy, Cao, Yanguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931430/
https://www.ncbi.nlm.nih.gov/pubmed/36547213
http://dx.doi.org/10.1002/psp4.12896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931430/
https://www.ncbi.nlm.nih.gov/pubmed/36547213
http://dx.doi.org/10.1002/psp4.12896

Ejemplares similares